# Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

> **NCT06297681** · — · UNKNOWN · sponsor: **Beijing Chao Yang Hospital** · enrollment: 40 (estimated)

## Conditions studied

- M-protein Related Cardiac Disease

## Interventions

- **DRUG:** Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin

## Key facts

- **NCT ID:** NCT06297681
- **Lead sponsor:** Beijing Chao Yang Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-03-15
- **Primary completion:** 2025-01-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-03-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06297681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06297681, "Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06297681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*